Conor Stewart
Research expert covering health & pharmaceuticals in the UK & Europe
Get in touch with us now| Characteristic | Share of children |
|---|---|
| DTaP (≥3 doses) | 80.4% |
| DTaP (≥4 doses) | 61.3% |
| Poliovirus (≥3 doses) | 80% |
| MMR (≥1 dose) | 78.3% |
| Hib (primary series) | 78.8% |
| Hib (full series) | 61.9% |
| HepB (birth dose) | 63.7% |
| HepB (≥3 doses) | 76.2% |
| VAR (≥1 dose) | 76.5% |
| PCV (≥3 doses) | 79.9% |
| PCV (≥4 doses) | 55.3% |
| HepA (≥1 dose) | 72.3% |
| Rotavirus (by age 8 mos) | 52% |
| Influenza (≥2 doses)*** | 37.8% |
| Combined 7-vaccine series | 42.5% |
| No vaccinations | 6% |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Loading statistic...
Download
Source
Sources
Release date
November 2023
More information
Region
United States
Survey time period
From 2019 to 2020
Number of respondents
422 respondents
Age group
0-24 months
Supplementary notes
DTaP = diphtheria, tetanus toxoids, and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; Hib = Haemophilus influenzae type b conjugate vaccine; MMR = measles, mumps, and rubella vaccine; PCV = pneumococcal conjugate vaccine; VAR = varicella vaccine.
Citation formats
